Rituximab

Preventing a first clotting event with aspirin may be the only truly effective treatment option in antiphospholipid syndrome, according to a presenter at the 2021 Congress of Clinical Rheumatology-East.

Reduced glucocorticoids alongside rituximab are noninferior to a regimen of high-dose glucocorticoids plus rituximab for remission induction at 6 months in patients with new ANCA-associated vasculitis, according to data published in JAMA.

This episode delves into the clinical presentation of serum sickness along with a dash of Arthus reaction, to boot!

The addition of copanlisib to rituximab extended PFS among patients with relapsed follicular lymphoma or marginal zone lymphoma, according to a subset analysis of the randomized phase 3 CHRONOS-3 trial.

Baseline rituximab or JAK inhibitor use for rheumatoid arthritis was associated with worse COVID-19 severity, compared with TNF-inhibitor use, according to a speaker at the EULAR 2021 Congress.

Treatment with a fixed interval of either 500 mg or 1,000 mg rituximab for at least 2 years is a “reasonable option” for patients with anti-neutrophil cytoplasmic autoantibody vasculitis upon achieving remission, according to a presenter here.

Patients who are immunosuppressed will “likely” need regular COVID-19 vaccine boosters in the future, according to Jeffrey R. Curtis, MD, MS, MPH, chair of the American College of Rheumatology COVID-19 Vaccine Clinical Guidance Task Force.

Vemurafenib plus rituximab induced durable complete responses in the majority of a small cohort of patients with relapsed or refractory hairy-cell leukemia, according to a phase 2 study published in The New England Journal of Medicine.

The ability to identify the features of Sjögren’s syndrome, and to seek payer approval for specific manifestations of the disease, is of paramount importance for the rheumatologist, according to a presenter at the 2021 Interdisciplinary Autoimmune Summit.

This week, the benefits of using telemedicine to address sleep disorders and provide cystic fibrosis care; rituximab may be an effective adjuvant treatment for systemic sclerosis and PAH; the FDA says facilities should move away from crisis capacity conservation measures; and researchers call for standardization to identify and categorize environmental exposures when assessing interstitial lung disease progression.